- Home
- WLII vs LFCR Comparison
WLII vs LFCR Comparison
Compare WLII & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$6.45
Company Overview
Basic Information| Metric | WLII | LFCR |
|---|---|---|
| Founded | 2025 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.1M | 190.9M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | WLII | LFCR |
|---|---|---|
| Price | $10.19 | $6.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.6K | ★ 578.3K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $10.16 | $3.63 |
| 52 Week High | $10.29 | $8.98 |
Technical Indicators
Market Signals| Indicator | WLII | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 75.36 |
| Support Level | N/A | $4.17 |
| Resistance Level | $10.29 | $6.65 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 0.00 | 92.06 |
Price Performance
Historical Comparison WLII
LFCR
About WLII Willow Lane Acquisition Corp. II Class A Ordinary Shares
Willow Lane Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.